JPRN-jRCT1031180387已完成2 期
Efficacy and safety of preoperative docetaxel chemotherapy and radical prostatectomy for untreated metastatic prostate cancer
Horie Shigeo0 个研究点目标入组 2 人开始时间: 2019年3月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 2
研究概览
简要总结
In both cases, the prostate cancer disease was well controlled, and the tumor marker PSA was less than 0.2 ng/mL as shown below. No.1: December 2022 PSA 0.122 ng/mL (slow PSA increase, but PSA <0.2) No.2: January 2023 PSA 0.008 ng/mL (good control) Regarding adverse events, the patients presented only minor reversible events with usual surgical care and docetaxel chemotherapy, and no events unique to this clinical trial occurred.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20age old 至 80age old（—）
- 性别
- Male
入选标准
- •metastatic prostate cancer
排除标准
- •Castration-Resistant Prostate Cancer, treated prostate cancer
研究者
相似试验
已完成
2 期
Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate CancerProstate CancerNCT01250717Beth Israel Deaconess Medical Center28
已完成
2 期
Docetaxel in Treating Patients With Stage II or Stage III Prostate CancerProstate CancerNCT00005096Dana-Farber Cancer Institute19
Unknown
不适用
Neoadjuvant Therapy With Docetaxel and Ketoconazole in Patients With High-Risk Prostate Cancer: A Pilot StudyProstate CancerNCT00870714Kansas City Veteran Affairs Medical Center20
进行中（未招募）
1 期
eoadjuvant docetaxel prior to radical prostatectomy for high risk localised prostate cancer. Evaluation of biological and functional imaging surrogates of therapy efficacy. - CANCAP01eoadjuvant docetaxel prior to radical prostatectomy for high risk localised prostate cancer. Evaluation of biological and functional imaging surrogates of therapy efficacyEUCTR2009-014491-21-GBCambridge University Hospitals NHS Trust15
尚未招募
不适用
Docetaxel Impact on Metastastic Prostate cancer patients: a quality of Life EvaluatioProstate cancerNL-OMON29025none300